Szilvia Bak-Kiss

Szilvia Bak-Kiss has been working in the field of biomedical research since 2011. From 2011 to 2015, they worked as a Research Student at the Department of Medical Biology, Medical School, University of Pécs, where they studied cellular signaling crosstalk in human tumor progression. During this time, they developed expertise in relevant molecular biology techniques such as Western blot, PCR, protein and DNA isolation, DNA fragmentation assay and in vitro cell culturing. Szilvia also contributed to an In-house Student Research Conference in 2015.

From 2015 to 2019, Szilvia Bak-Kiss worked as a PhD Student at the Molecular Immunotherapy Group, Institute for Transfusion Medicine, Hannover Medical School. Here, they studied human CMV and EBV-specific T-cell functionality in hematological malignancies for personalized antiviral T-cell immunotherapeutic. Her research areas included personalized immunosuppression with mTOR- and calcineurin inhibitors in transplant patients, reversing T-cell exhaustion in post-transplant malignancies by checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4, and generation of CAR T cells against tumor antigens. Szilvia also contributed to two conferences in 2018.

Since 2019, Szilvia Bak-Kiss has been working as a Postdoctoral Researcher at Gene Center Munich. In 2022, they will begin working as a Scientist at iOmx Therapeutics AG.

Szilvia Bak-Kiss completed their High School education at the Táncsics Mihály Secondary Grammar School in 2009. Szilvia then went on to receive their Bachelor's Degree in Biology/Biological Sciences, General from the University of Pécs in 2013. Following that, they obtained their Master's Degree in Medical Biotechnology from the Medical School at the University of Pécs in 2015. Finally, they completed their Doctor of Philosophy (Ph.D.) in Molecular Immunology from the Medizinische Hochschule Hannover in 2018.